SEC Form 4 · accession 0001193125-26-323640
Beam Therapeutics Inc. · BEAM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy Simon
Officer — Chief Medical Officer
Period of report
Jul 27, 2026
Accepted (ET)
Jul 29, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001745999
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 27, 2026 | S | 16,667 | $25.7417 | D | 85,696 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.32 to $26.05, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.